Dr Lodewyk Wessels discusses an initiative set up by the Netherland Cancer Institute and the Welcome Trust Sanger Institute working to assess the susceptibility of different cancer cell lines to different drugs.

This project is aimed to establish biomarkers for drug susceptibility helping to identify which patients will show drug resistant and potentially helping clinicians understand and overcome this resistance. Dr Wessels outlines the findings so far, and explains what implications this work could have on future treatment programmes.